Drug offers huge potential for endometriosis

E2MATE is a steroidal derivative, based upon the sex steroid oestrogen.

A recent clinical study on a drug designed at the University has confirmed its potential in targeting the gynaecological disease endometriosis.

The study entitled 'Synergistic Effects of E2MATE and Norethindrone Acetate on Steroid Sulfatase Inhibition: A Randomized Phase I Proof-of-Principle Clinical Study in Women of Reproductive Age' appeared in the journal Reproductive Sciences earlier this year.

Endometriosis is a benign disease which leads to and infertility. With an estimated 80 million sufferers worldwide, the disease is still poorly understood. The discovery of is critical as most treatments have unpleasant side effects and current therapies have proved inadequate.

E2MATE, also known as PGL2001, was first designed and chemically synthesised in the Medicinal Chemistry Group of our Department of Pharmacy & Pharmacology.

The scientific basis for these trials was founded on a paper published in 2008 by teams at the University and Imperial College, London on Irosustat – another drug originating from the University. The paper showed that the drug, which has reached widespread Phase II cancer trials, has potential for the treatment of .

Commenting on the developments Professor Potter, who was the lead on both the E2MATE and Irosustat projects, said: "The most rewarding thing for any Drug Discovery Group is to see a drug we have designed in the lab overcome the multitude of very difficult hurdles and finally be administered to humans.

"Only the tiniest fraction of all such development candidates ever makes it this far, even in the pharma industry, as they require multidisciplinary teamwork and a multi-million pound budget. I am very encouraged that both our underpinning scientific concepts and the actual itself could translate into clinical benefit for a real unmet need".

More information: "Synergistic Effects of E2MATE and Norethindrone Acetate on Steroid Sulfatase Inhibition: A Randomized Phase I Proof-of-Principle Clinical Study in Women of Reproductive Age." Reproductive Sciences 1933719114522526, first published on March 6, 2014 DOI: 10.1177/1933719114522526

add to favorites email to friend print save as pdf

Related Stories

Research paper on cancer drug accorded 'VIP' status

Oct 27, 2011

A paper on the anti-cancer drug Irosustat, designed by researchers at the University of Bath, has been awarded 'Very Important Paper' status by the medicinal chemistry journal ChemMedChem, including a spec ...

Chinese herbs for endometriosis

Jul 08, 2009

Chinese herbal medicine (CHM) may relieve symptoms in the treatment of endometriosis. A systematic review by Cochrane Researchers found some evidence that women had comparable benefits following laparoscopic surgery and suffered ...

Recommended for you

Sierra Leone faces criticism over Ebola shutdown

18 hours ago

Sierra Leone began the second day of a 72-hour nationwide shutdown aimed at containing the spread of the deadly Ebola virus on Saturday amid criticism that the action was a poorly planned publicity stunt.

Presence of peers ups health workers' hand hygiene

Sep 19, 2014

(HealthDay)—The presence of other health care workers improves hand hygiene adherence, according to a study published in the October issue of Infection Control and Hospital Epidemiology.

Sierra Leone streets deserted as shutdown begins

Sep 19, 2014

Sierra Leone's normally chaotic capital resembled a ghost town on Friday as residents were confined to their homes for the start of a three-day lockdown aimed at halting the deadly Ebola epidemic.

Sierra Leone launches controversial Ebola shutdown

Sep 19, 2014

Sierra Leone on Friday launched a controversial three-day shutdown to contain the deadly spread of the Ebola virus, as the UN Security Council declared the deadly outbreak a threat to world peace.

User comments